Skip to main content
. 2022 Mar 24;13:834342. doi: 10.3389/fimmu.2022.834342

Figure 2.

Figure 2

Therapeutic strategies targeting IgG4 class switch via IL-4. Altrakincept, pascolizumab, dupilumab, dectrekumab, AMG-317 and pitrakinra have been developed to prevent the binding of IL-4 to its receptor by blocking the soluble IL-4 or targeting its receptor itself. Targeting IL-4 may help to avert IgG4 class switch and therefore, the development of IgG4-RLD and IgG4-AID. Figure created using Biorender.